Cagrilintide vs Orforglipron | Research Comparison | QSC

Cagrilintide vs Orforglipron

Mechanism, Phase 2 data, and research applications compared

Shop Both at QSC →

Factor Cagrilintide Orforglipron
Receptor AMY1R (amylin-1) Non-peptide GLP-1R agonist
Best Trial Result −15.6% CagriSema (32wks) −14.7% (36wks)
At QSC ✓ In Stock ✓ In Stock
Research analysis: Different mechanisms: AMY1R vs GLP-1R. Complementary combination potential; orforglipron is oral.
Research Use Only. All QSC products for in vitro laboratory research only.
Peptides
Orals
Oils
Search
Contact